Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Hyperkalemia and maintenance of renin–angiotensin system inhibitor therapy after initiating SGLT-2 or DPP-4 inhibitors

Nephrology Dialysis Transplantation(2024)10.1093/ndt/gfae227Source: DataRank Database

Hyperkalemia and maintenance of renin–angiotensin system inhibitor therapy after initiating SGLT-2 or DPP-4 inhibitors is a research paper published in Nephrology Dialysis Transplantation (2024). On theSindex it has a DataRank of 0. It has been cited 4 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access4 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (9 grants)Impact (FWCI 1.13)OA: hybridTopics (48)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (8)

Yang Xu ORCID,Anne‐Laure Faucon ORCID,Tao Huang ORCID,Marie Evans ORCID,Jung‐Im Shin ORCID

Live enrichment

PubMed:39384578 PMC:PMC12035535 OpenAlex:https://openalex.org/W4403307910

National Institutes of Health

Grant: R01 DK115534

National Natural Science Foundation of China

Grant: 82304245

NIDDK NIH HHS

Grant: R01 DK139324

Swedish Research Council

Grant: unidentified

unidentified

National Institutes of Health

Grant: 2R01DK115534-06

Maximizing The Benefit of Therapy in CKD

Dutch Research Council (NWO)

Young Scientists Fund

Swedish Research Council

Swedish Heart and Lung Foundation

FWCI

1.13

Citation Percentile

0.8%

Citation Trend

2025

2026

hybridLicense: cc-by-nc

journalhttps://academic.oup.com/ndt/advance-article-pdf/doi/10.1093/ndt/gfae227/59661502/gfae227.pdf

publisherhttps://academic.oup.com/ndt/advance-article-pdf/doi/10.1093/ndt/gfae227/59661502/gfae227.pdf

publisherhttps://academic.oup.com/ndt/advance-article-pdf/doi/10.1093/ndt/gfae227/60470588/gfae227.pdf

publisherhttps://academic.oup.com/ndt/article-pdf/40/5/956/60470588/gfae227.pdf

journalhttps://doi.org/10.1093/ndt/gfae227

Fields of Study

Potassium and Related DisordersDiabetes Treatment and ManagementCoagulation, Bradykinin, Polyphosphates, and Angioedema03 medical and health sciences0302 clinical medicine

MeSH Terms

Sodium-Glucose Transporter 2 InhibitorsAgedAngiotensin-Converting Enzyme InhibitorsDiabetes Mellitus, Type 2FemaleFollow-Up StudiesHumansHyperkalemiaMaleMiddle AgedPrognosisRenin-Angiotensin SystemRisk FactorsSwedenDipeptidyl-Peptidase IV Inhibitors

Keywords

MedicineHyperkalemiaRenin–angiotensin systemPharmacologyRenin inhibitorACE inhibitorAngiotensin-converting enzymeInternal medicineBlood pressureType 2 diabetesepidemiologySodium-glucose Cotransporter-2 InhibitorsTarget Trial EmulationMaleSwedenDipeptidyl-Peptidase IV InhibitorsAngiotensin-Converting Enzyme InhibitorsMiddle AgedPrognosisRenin-Angiotensin SystemDiabetes Mellitus, Type 2Risk FactorsHumansOriginal ArticleFemaleSodium-Glucose Transporter 2 InhibitorsAgedFollow-Up Studies

Sustainable Development Goals

SDG 0: Good health and well-being